炎症性肠病患者中艰难梭菌感染发生率更高
该研究利用 Manitoba 炎症性肠病流行病学数据库与 Manitoba 健康艰难梭菌感染数据库,纳入 2005 年 7 月 1 日至 2014 年 3 月 31 日期间经实验室确诊的艰难梭菌感染个体,比较有/无炎症性肠病者的艰难梭菌感染发生率与死亡率。结果显示炎症性肠病患者的艰难梭菌感染风险为无炎症性肠病者的 4.8 倍,溃疡性结肠炎与克罗恩病之间无差异,研究期间两组艰难梭菌感染发生率均未上升;炎症性肠病患者感染后死亡率低于无炎症性肠病者(HR 0.65,95%CI 0.44-0.96)。
要点
- 炎症性肠病患者艰难梭菌感染风险为无炎症性肠病者的 4.8 倍,溃疡性结肠炎与克罗恩病之间无差异。
- 炎症性肠病患者中,使用皮质类固醇、英夫利西单抗或阿达木单抗、甲硝唑、住院、更多门诊就诊、炎症性肠病病程较短及合并症较多与艰难梭菌感染风险增加相关。
- 炎症性肠病患者艰难梭菌感染后死亡率低于无炎症性肠病者(HR 0.65,95%CI 0.44-0.96)。
核心结论
- 炎症性肠病患者中艰难梭菌感染发生率不再上升;研究识别出炎症性肠病患者特有的艰难梭菌感染危险因素;艰难梭菌感染对无炎症性肠病者死亡率的增加幅度大于炎症性肠病患者。
研究设计与样本
- 基于人群的队列研究,检索 University of Manitoba 炎症性肠病流行病学数据库与 Manitoba 健康艰难梭菌感染数据库,纳入 2005 年 7 月 1 日至 2014 年 3 月 31 日期间经实验室确诊的艰难梭菌感染个体,比较有/无炎症性肠病者。
- 采用 joinpoint 回归分析发生率的时问趋势,多因素 Cox 回归分析艰难梭菌感染发生率与感染后死亡率的组间差异,条件 logistic 回归确定炎症性肠病患者中艰难梭菌感染的预测因素。
主要发现
- 炎症性肠病患者艰难梭菌感染风险为无炎症性肠病者的 4.8 倍,溃疡性结肠炎与克罗恩病之间无差异。
- 研究期间两组艰难梭菌感染发生率均无上升。
- 炎症性肠病患者中,暴露于皮质类固醇、英夫利西单抗或阿达木单抗、甲硝唑、住院、更多门诊就诊、炎症性肠病病程较短及合并症较多与艰难梭菌感染风险增加相关。
- 艰难梭菌感染使有/无炎症性肠病者死亡率均增加,但炎症性肠病患者感染后死亡率低于无炎症性肠病者(HR 0.65,95%CI 0.44-0.96)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Studies of Clostridium difficile infections (CDIs) among individuals with inflammatory bowel disease (IBD) have used data from single centers or CDI administrative data codes of limited diagnostic accuracy. We determined the incidence, risk factors, and outcomes after CDI in a population-based cohort of patients with IBD and laboratory confirmation diagnoses of CDI. METHODS: We searched the University of Manitoba IBD Epidemiology Database and Manitoba Health CDI databases to identify individuals with CDI, with or without IBD, from July 1, 2005 through March 31, 2014. Time trends of incidence were assessed using joinpoint regression. Multivariable Cox regression analyses were performed to assess differences in CDI incidence rates and mortality after CDI between individuals with and without IBD. Conditional logistic regression was performed to determine predictors of CDI among individuals with IBD. RESULTS: Individuals with IBD had a 4.8-fold increase in risk of CDI than individuals without IBD; we found no difference between individuals with ulcerative colitis vs Crohn's disease. There was no increase in CDI incidence over the study time period in either group. Among individuals with IBD, exposure to corticosteroids, infliximab or adalimumab, metronidazole, hospitalizations, higher ambulatory care visits, shorter duration of IBD, and higher comorbidities were associated with an increased risk of CDI. Although CDI increased mortality among individuals with and without IBD, there was lower mortality after CDI among individuals with IBD than without IBD (hazard ratio, 0.65; 95% confidence interval, 0.44-0.96). CONCLUSIONS: CDI incidence is no longer increasing among individuals with IBD. We identified unique risk factors for CDI in patients with IBD. CDI is associated with a greater increase in mortality among individuals without IBD than with IBD.
引用
- Singh H, Nugent Z, Yu BN, et al. Higher Incidence of Clostridium difficile Infection Among Individuals With Inflammatory Bowel Disease. Gastroenterology. 2017. PMID: 28479377. doi:10.1053/j.gastro.2017.04.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。